Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04988945 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 years later Dec 1, 2024 → Dec 31, 2028
See other at-risk trials from The University of Hong Kong

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 1, 2024 to Dec 31, 2028 Show 6 more changesShow less
    • Enrollment closed, study ongoing
    • Study completion pushed from Dec 1, 2026 to Dec 31, 2028
    • Eligibility criteria expanded, about 70 words
    • Secondary endpoints: details revised at 5 of 7 entries
    • Site details revised at 2 of 2 sites
    • Publications: details revised at 9 of 9 entries
  2. Primary completion date: Dec 1, 2022 to Dec 1, 2024v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a prospective phase II, single arm mono-institutional study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of the sequential administration of trans-arterial chemo-embolization (TACE) and stereotactic body radiotherapy (SBRT) with immune checkpoint inhibitors in unresectable hepatocellular carcinoma (HCC) patients.
Trial Details
NCT Number NCT04988945
Lead Sponsor The University of Hong Kong
Conditions
(from sponsor)		 HCC
Related terms Carcinoma, Hepatocellular, Liver Neoplasms
Enrollment 33 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov